ReEmerge exits stealth with $37M to restore brain function after injury
What's the deal? ReEmergeDealroom has a profile for this one. Try Dealroom →, a Minnesota-based MedTech startup, exited stealth on September 15 with an oversubscribed $37 million Series A. US Venture Partners (USVP) and SantéDealroom has a profile for this one. Try Dealroom → co-led the round, with participation from Oxford Science EnterprisesDealroom has a profile for this one. Try Dealroom →, 415 CapitalDealroom has a profile for this one. Try Dealroom →, IAG Capital PartnersDealroom has a profile for this one. Try Dealroom →, The Vertical GroupDealroom has a profile for this one. Try Dealroom →, and Dendrion Ventures.
What's the endgame? ReEmerge is developing Cognitive Network Restoration Therapy (CNRT), which targets neural networks in the central thalamus, a brain hub tied to attention, arousal, and executive function. Rather than bypassing damaged pathways, CNRT aims to drive underactive but viable neural circuits to reverse cognitive deficits years after an injury.
The technology grew out of decades of research by Nicholas Schiff, professor of neuroscience at Weill Cornell Medicine, alongside colleagues at Stanford University and the University of Utah. A pilot study, published in Nature Medicine , showed patients regaining cognitive function.
What's the money for? The proceeds will fund a clinical study evaluating CNRT in its first indication, traumatic brain injury (TBI). The prospective, single-arm, multicenter trial will enrol up to 40 patients with chronic moderate-to-severe TBI, while ReEmerge advances technology development and expands clinical and regulatory operations.
Why it matters: Patients with chronic cognitive impairment have historically had few therapeutic options. "CNRT could offer people living with TBI something they have too often been told not to expect, namely the possibility of meaningful cognitive recovery," said Auriel August, principal at Santé.
The signal: ReEmerge is betting it can shift chronic brain-injury care from rehabilitation to restoration. As Schiff put it, the goal is to help "many patients, who have historically had limited therapeutic options."
Read more: finanznachrichten.de
Image credit: Generated with Gemini
